Hidradenitis Suppurativa
An Introduction to Hidradenitis suppurativa
Hidradenitis suppurativa (HS), also known as acne inversa, is a chronic skin condition characterized by painful, recurrent nodules and abscesses that form in areas where skin rubs together, such as the armpits, groin, buttocks and under the breasts. It primarily affects hair follicles and sweat glands, leading to inflammation, scarring and the formation of tunnels under the skin known as sinus tracts. The exact underlying cause of hidradenitis suppurativa is unknown, although research suggests that there may be an association between HS development and hormones, genetics, smoking or excess weight. This condition can significantly impact a person’s quality of life, causing pain, discomfort and potential emotional distress due to the visibility of the lesions. The management of hidradenitis suppurativa involves a combination of medical treatments such as antibiotics, anti-inflammatory drugs and biologics. Surgical interventions may be considered to drain abscesses, remove scar tissue or excise affected areas. Lifestyle changes, weight management and maintaining good hygiene can also help alleviate symptoms. Improvements in diagnosis times and further research are essential in providing better support and treatment options for individuals living with hidradenitis suppurativa.
Our supporting partners do not constitute an endorsement of the content on this page.
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
We are delighted to welcome Dr Benjamin Kaffenberger, Associate Professor of Dermatology at The Ohio State University Wexner Medical Center, to the touchDERMATOLOGY Expert Faculty. A leading expert in complex skin conditions such as pyoderma gangrenosum, DRESS syndrome, and SJS/TEN, Kaffenberger brings extensive clinical and research experience in drug reactions, wound care, and hospital dermatology.
As 2025 unfolds, the field of dermatology is set for some significant advancements. To get a glimpse of what’s ahead, we turned to our esteemed Expert Faculty members, who shared their expert insights on what they think will be the key innovations shaping this year. From the most exciting trends of 2024 that are gaining momentum to the next breakthroughs poised to redefine patient care, here’s what they had to say.
A new study, presented at the 2024 European Academy of Dermatology and Venereology (EADV) Congress, reveals the potential of semaglutide, a GLP-1 receptor agonist, in treating hidradenitis suppurativa (HS). This research suggests semaglutide, already approved for obesity and diabetes treatment, may reduce HS flare-ups and improve quality of life in obese patients. Learn how this promising therapy could mark a breakthrough in managing this chronic skin condition. Read the full study published in the British Journal of Dermatology."
Recent advancements made in understanding the pathology of inflammatory skin conditions have enabled JAK inhibitors, initially developed for haematology over 20 years ago, to be investigated for dermatological use. In this episode, Dr William (Bill) Damsky discusses JAK inhibitors’ journey from proof-of-concept to treating a wide range of skin conditions, their future impact on rare diseases and the debate around safety.
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
